14 Peptides Returning to Legal Compounding Status
On February 27, 2026, HHS Secretary Robert F. Kennedy Jr. announced that approximately 14 of the 19 peptides placed on the FDA's Category 2 restricted list in late 2023 will be reclassified to Category 1 — restoring legal compounding access through licensed pharmacies with a physician's prescription.
What this means in practice: 503A compounding pharmacies can legally prepare these peptides again once the FDA formally publishes the updated list. As of this writing, the formal reclassification has been announced but not yet officially published.
Peptides likely staying on Category 2: Melanotan II, GHRP-2, GHRP-6, PEG-MGF, and LL-37 — compounds with weaker human safety data or more significant side effect profiles.
This is the most significant regulatory shift in the peptide space since the original 2023 restrictions. For providers, the practical takeaway is clear: start rebuilding your peptide formulary relationships with licensed compounding pharmacies now. The formal list could drop any day. Don't wait until demand spikes and lead times stretch.
Reclassification to Category 1 does NOT mean FDA approval. These remain off-label therapeutics requiring physician supervision, proper dosing protocols, and ongoing monitoring. CoA verification remains essential.
Industry Shakeup: Peptide Sciences Shuts Down
On March 6, 2026, Peptide Sciences — the largest grey-market research peptide vendor in the U.S. — voluntarily shut down operations. No warning. No refund process. No forwarding address.
Why it matters: The closure followed 12 months of escalating FDA enforcement — warning letters to multiple vendors, warehouse raids, and criminal prosecutions. The DOJ secured guilty pleas from Tailor Made Compounding LLC and All American Peptide, establishing legal precedent that selling peptides for human use (regardless of "research use only" labels) can result in criminal charges and millions in forfeitures.
The bigger picture: This isn't an isolated event. At least seven research peptide companies shut down in 2025. The grey-market model that sustained much of the peptide ecosystem for the past decade is collapsing — and it's collapsing at the exact moment that legal compounding access is expanding through the Category 1 reclassification.
If you have patients who were sourcing through grey-market vendors, now is the time to transition them to physician-supervised protocols through licensed 503A pharmacies. The regulatory path is clearing for legitimate access. There's no reason to stay in the grey zone.
Sourcing Intel: What to Watch For
With 14 peptides returning to legal compounding and grey-market supply disappearing, demand for GMP-grade peptide APIs is about to surge. Here's what we're seeing:
Lead times are stretching. Chinese GMP manufacturers are already reporting increased inquiry volume from U.S. compounding pharmacies. BPC-157 and Thymosin Alpha-1 are seeing the most demand. If you're planning to stock these, get your purchase orders in early.
CoA quality varies wildly. Not all Certificates of Analysis are created equal. The minimum you should accept: HPLC purity ≥98%, mass spectrometry identity confirmation, endotoxin testing, and residual solvent testing. If a supplier can't provide all four, walk away.
Price pressure is coming. As demand increases, expect per-gram API costs to rise 15–25% in the near term before stabilizing. Lock in pricing now if you can.
Study Worth Reading
Oral BPC-157 for Gut Barrier Integrity — While most BPC-157 research has focused on injectable administration, emerging preclinical data continues to support oral bioavailability for gastrointestinal applications. Gut barrier integrity is increasingly recognized as a key factor in metabolic syndrome, insulin resistance, and systemic inflammation. As BPC-157 returns to legal compounding status, expect to see more clinical interest in oral protocols for IBS, leaky gut, and post-antibiotic recovery.
Reader Q&A
This is Issue #1. We don't have reader questions yet — but we want yours. Reply to [email protected] with any question about peptide science, sourcing, protocols, or regulations. We'll answer the best ones in depth in future issues.
Get the Peptide Intelligence Briefing delivered to your inbox every month. Free. No ads.
Subscribe to the Briefing →